{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'solicited adverse events following vaccination. Injection site reactogenicity will be assessed', 'separately for COVID-19 vaccine and IIV4 or placebo as described in Table 8.', 'Table 8. Injection-site Reactogenicity Grading', 'Local Reaction to', 'Mild (Grade 1)', 'Moderate (Grade', 'Severe (Grade 3)', 'Potentially Life', 'Injectable Product', '2)', 'Threatening (Grade 4)', 'Pain', 'Does not', 'Emergency room (ER) visit', 'interfere with', 'or hospitalization', 'Interferes with', 'activity', 'Prevents daily', 'activity', 'activity', 'Induration/Swelling', '2.5 - 5 cm', '5.1 - 10 cm', '> 10 cm', 'Emergency room (ER) visit', 'or hospitalization', 'Erythema/Redness', '2.5 - 5 cm', '5.1 - 10 cm', '> 10 cm', 'Emergency room (ER) visit', 'or hospitalization', 'Axillary (underarm)', 'Does not', 'Interferes with', 'Prevents daily', 'Emergency room (ER) visit', 'swelling or', 'interfere with', 'activity', 'activity', 'or hospitalization', 'tenderness', 'activity', 'ipsilateral to side', 'of injection', 'Participants will also be queried during Visits 2, 3, and 4 on common post-injection systemic', 'symptoms as described in Table 9.', 'Table 9. Systemic Reactogenicity Grading (FDA modified)', 'Systemic', 'Mild (Grade 1)', 'Moderate (Grade 2)', 'Severe (Grade 3)', 'Potentially Life', 'Threatening (Grade 4)', 'Fever (\u00b0C)', '38.0 38.4', '38.5 38.9', '39.0 - 40.0', '> 40.0', '(\u00b0F)', '100.4 101.1', '101.2 102.0', '102.1-104.0', '> 104.0', 'Some interference with', 'ER visit or', 'Nausea/vomiting', 'No interference with activity', 'Prevents daily', 'or 1 - 2 episodes/24 hours', 'activity or > 2 episodes/24', 'hospitalization', 'activity', 'hours', '2 - 3 loose stools/24 hours', '4-5 loose stools/24 hours', '6 or more watery', 'ER visit or', 'Diarrhea', 'stools or > 24', 'hospitalization', 'hours', 'Does not interfere with', 'Some interference with', 'Prevents daily', 'ER visit or', 'Headache', 'activity', 'activity', 'routine activity', 'hospitalization', 'Does not interfere with', 'Some interference with', 'Prevents daily', 'ER visit or', 'Fatigue', 'activity', 'activity', 'routine activity', 'hospitalization', 'Does not interfere with', 'Some interference with', 'Prevents daily', 'ER visit or', 'Myalgia', 'activity', 'activity', 'routine activity', 'hospitalization', 'Does not interfere with', 'Some interference with', 'Prevents daily', 'ER visit or', 'Arthralgia', 'activity', 'activity', 'routine activity', 'hospitalization', 'Does not interfere with', 'Some interference with', 'Prevents daily', 'ER visit or', 'Chills', 'activity', 'activity', 'routine activity', 'hospitalization', '41']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'During Visits 2, 3, 4 participants will be encouraged to report any significant adverse events', 'occurring within 7 days of the vaccination visits and during Visits 2, 3, 4, 5, and 6 any serious', 'adverse events in an open-ended question format, e.g. \"How are you doing? Are you having', 'any medical or clinical problems? If so, please tell me about them. Participants who report', 'severe solicited or unsolicited adverse events or express any concern about', 'symptoms/unsolicited events will be encouraged to follow up with their primary care provider.', 'Study staff will assist with coordination of referral appointments as necessary. Medical records', 'will be obtained and reviewed for the occurrence of any adverse events, serious adverse events', 'or adverse events of special interest throughout the study period.', 'Unsolicited adverse events (AEs) will be collected and reported for the 7 days following each', 'vaccine visit. Serious adverse events (SAEs) and adverse events of special interest (AESI) will', 'be collected and reported during the entire study period [i.e. from enrollment through 120 days', 'following enrollment]. Unsolicited AEs, SAEs, and AESIs will be graded as follows.', 'Mild (Grade 1)', 'Moderate (Grade 2)', 'Severe (Grade 3)', 'Potentially Life Threatening', '(Grade 4)', 'Does not interfere', 'Interferes with activity', 'Prevents daily activity', 'Emergency room (ER) visit or', 'with activity', 'hospitalization', 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation', 'subject administered a pharmaceutical product and which does not necessarily have to have a', 'causal relationship with this treatment.', 'An SAE is defined as an AE that meets one of the following conditions:', 'Results in death during the period of protocol-defined surveillance', 'Is life-threatening (defined as immediate risk of death at the time of the event)', 'Requires inpatient hospitalization or prolonged hospitalization during the period of', 'protocol-defined surveillance', 'Results in congenital anomaly or birth defect', 'Results in a persistent or significant disability/incapacity', 'Any other important medical event that may not result in death, be life threatening, or', 'require hospitalization, may be considered an SAE when, based upon appropriate', 'medical judgment, the event may jeopardize the participant and may require medical or', 'surgical intervention to prevent one of the outcomes listed above. Examples of such', 'medical events include allergic bronchospasm requiring intensive treatment in an', 'emergency room or at home, blood dyscrasias or convulsions that do not result in', 'inpatient hospitalization, or the development of drug dependency or drug abuse.', 'An adverse event of special interest (AESI) includes the following:', 'COVID-19 illness', 'Multisystem inflammatory syndrome', 'Guillain-Barre syndrome', 'Allergic type reactions (including anaphylaxis, hives, or facial and limb swelling occurring', 'within 7 days of a vaccination visit)', 'Myocarditis or pericarditis', '42']\n\n###\n\n", "completion": "END"}